Shots:
- AstraZeneca has reported P-III (MATTERHORN) trial data assessing perioperative Imfinzi + FLOT (fluorouracil, leucovorin, oxaliplatin, & docetaxel) vs PBO + FLOT in 948 pts with stage II-IVA G/GEJ cancers
- Pts received Imfinzi (1500mg) + FLOT or PBO + FLOT for Q4W × 2 cycles before surgery followed by Imfinzi or PBO for Q4W × 12 cycles (2 cycles with FLOT CT + 10 cycles as monotx.)
- Trial showed improved EFS (1EP) & a favorable trend with OS (2EP), which will be assessed in final analysis. Data to be presented at future meetings & shared with global health authorities
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports Interim Data from P-III (SERENA-6) Trial of Camizestrant to Treat Advanced Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
